Features of recurrence of endometrioid type endometrial cancer of I stage

Authors

  • O.M. Movchan National Cancer Institute, Kyiv 03022, Ukraine
  • V.S. Svintsitskiy National Cancer Institute, Kyiv 03022, Ukraine
  • N.P. Tsip National Cancer Institute, Kyiv 03022, Ukraine
  • S.V. Nespryadko National Cancer Institute, Kyiv 03022, Ukraine
  • O.I. Bublіieva National Cancer Institute, Kyiv 03022, Ukraine
  • N.P. Iurchenko R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology

DOI:

https://doi.org/10.32471/exp-oncology.2312-8852.vol-43-no-4.17052

Keywords:

chemotherapy, combined therapy, endometrial cancer, radiation therapy, relapse, surgical treatment, survival

Abstract

Summary. The aim of this study was to determine the rates of recurrences of stage I endometrial cancer (EC) and features of their localization depending on the clinical and pathological characteristics of the tumor and methods of patients’ treatment. Patients and Methods: The study included 968 patients with stage I endometrioid EC, who underwent surgical treatment in the Department of Oncogynecology of the National Cancer Institute in 2015–2019. Surveillance of patients lasted from January 2015 to December 2020, with a minimum follow-up period of 1 year from the date of surgery. Adjuvant radiation or chemotherapy was performed depending on the clinical and pathological characteristics of the EC case. Results: During the follow-up period, recurrences were observed in 7.0% of cases and were most often found in stage IC of low differentiation grade. It was found that during surgical treatment without adjuvant therapy relapses occurred in 12–36 months after the start of treatment, with adjuvant radiation therapy — in 6–18 months, and with adjuvant chemotherapy — in 32–60 months. Recurrences most often occurred in patients with EC who underwent surgical treatment in combination with chemotherapy (p < 0.05). The lowest number of recurrences was recorded among patients who underwent surgery as an only treatment. The best 5-year survival rate was observed in the group of patients with surgical treatment (93%), and the worst — in the patients treated with combination of surgery and chemotherapy (57%). In patients without recurrences, the survival rate after treatment was 97%, while in patients diagnosed with relapses, the survival rate was 65%. Conclusion: Despite the predominantly favorable course of EC stage I, some patients develop relapses. The rate and localization of recurrences depend on the histological structure of the tumor and treatment regimens of the EC patients.

References

Fedorenko Z, Goulak L, Gorokh Ye, et al. Cancer in Ukraine: incidence, mortality, activities of the oncological service 2020; 22: 146 p.

National Cancer Institute. Endometrial cancer treatment Physician Data Query (PDQ). 2021. http://www.cancer.gov/ cancertopics/pdq/treatment/endometrial/healthprofessional

Colombo N, Creutzberg C, Amant F, et al. ESMO-ESGO-ESTRO consensus conference on endometrial cancer: diagnosis, treatment and follow-up. Int J Gynecol Cancer 2016; 26: 2–30. https://doi.org/10.1093/annonc/mdv484

ACOG. ACOG practice bulletin, clinical management guidelines for obstetrician-gynecologists, number 65, August 2005: management of endometrial cancer. Obstet Gynecol 2005; 106: 413Y425. https://doi.org/10.1097/00006250-200508000-00050

Bendifallah S, Canlorbe G, Collinet P, et al. Just how accurate are the major risk stratification systems for early-stage endometrial cancer? Br J Cancer 2015; 112: 793–801. https://doi.org/10.1038/bjc.2015.35

Brennan DJ, Hackethal A, Mann KP, et al. Serum HE4 detects recurrent endometrial cancer in patients undergoing routine clinical surveillance. BMC Cancer 2015; 15: 33. https://doi.org/10.1186/s12885-015-1028-0

Harrison RF, He W, Fu S, et al. National patterns of care and fertility outcomes for reproductive-aged women with endometrial cancer or atypical hyperplasia. Am J Obstet Gynecol 2019; 221: 474.e1–11. doi:10.1016/j.ajog.2019.05.029

Concin N, Matias-Guiu X, Vergote I, et al. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. Int J Gynecol Cancer 2021; 31: 12–39. https://doi.org/10.1136/ijgc-2020-002230

Androutsopoulos G, Michail G, Adonakis G, et al. Current treatment approach of endometrial cancer. Int J Clin Ther Diagn 2015; S1(3): 8–11. doi:10.19070/2332-2926-SI01003

Colombo N, Preti E, Landoni F, et al. Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013; 24: vi33Yvi38. https://doi.org/10.1093/annonc/mdt353

de Boer SM, Nout RA, Jürgenliemk-Schulz IM, et al. Long-term impact of endometrial cancer diagnosis and treatment on health-related quality of life and cancer survivorship: results from the randomized PORTEC-2 trial. Int J Radiat Oncol Biol Phys 2015; 93: 797–809. https://doi.org/10.1016/j.ijrobp.2015.08.023

Nout RA, Smit VTHBM, Putter H, et al. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non- inferiority, randomised trial. Lancet 2010; 375: 816–23. https://doi.org/10.1038/s41416-018-0310-8

Creutzberg CL, Nout RA, Lybeert MLM, et al. Fifteen-year radiotherapy outcomes of the randomized PORTEC-1 trial for endometrial carcinoma. Int J Radiat Oncol Biol Phys 2011; 81: e631–8. https://doi.org/10.1016/j.ijrobp.2011.04.013

Matei D, Filiaci VL, Randall M, et al. A rando¬mized phase III trial of cisplatin nd tumor volume directed irradiation followed by carboplatin and paclitaxel vs. carboplatin and paclitaxel for optimally debulked, advanced endometrial carcinoma. J Clin Oncol 2017; 35: 5505. doi: https://doi.org/10.1200/JGO.17.00146

de Boer SM, Powell ME, Mileshkin L, et al. Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre, randomised, phase 3 trial. Lancet Oncol 2016; 17: 1114–26. https://doi.org/10.1016/S1470-2045(16)30120-6

Sorbe B, Horvath G, Andersson H, et al. External pelvic and vaginal irradiation versus vaginal irradiation alone as postoperative therapy in medium-risk endometrial carcinoma — a prospective randomized study. Int J Radiat Oncol Biol Phys 2012; 82: 1249–55. doi:10.1016/j.ijrobp.2011.04.014

Randall ME, Filiaci V, McMeekin DS, et al. Phase III trial: adjuvant pelvic radiation therapy versus vaginal brachytherapy plus paclitaxel/carboplatin in high-Intermediate and high-risk early stage endometrial cancer. J Clin Oncol 2019; 37: 1810–8. https://doi.org/10.1200/JCO.18.01575

Matei D, Filiaci V, Randall ME, et al. Adjuvant chemotherapy plus radiation for locally advanced endometrial cancer. N Engl J Med 2019; 380: 2317–26. https://doi.org/10.1056/NEJMoa1813181

de Boer SM, Powell ME, Mileshkin L, et al. Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial. Lancet Oncol 2019; 20: 1273–85. https://doi.org/10.1016/S1470-2045(18)30079-2

Downloads

Published

26.05.2023

How to Cite

Movchan, O., Svintsitskiy, V., Tsip, N., Nespryadko, S., Bublіieva O., & Iurchenko, N. (2023). Features of recurrence of endometrioid type endometrial cancer of I stage. Experimental Oncology, 43(4), 365–369. https://doi.org/10.32471/exp-oncology.2312-8852.vol-43-no-4.17052

Issue

Section

Original contributions

Most read articles by the same author(s)